Compare AWI & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AWI | BLTE |
|---|---|---|
| Founded | 1860 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.6B |
| IPO Year | 1994 | 2021 |
| Metric | AWI | BLTE |
|---|---|---|
| Price | $177.22 | $160.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $208.83 | $198.00 |
| AVG Volume (30 Days) | ★ 326.2K | 132.4K |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | ★ 17.61 | N/A |
| EPS | ★ 7.08 | N/A |
| Revenue | ★ $1,620,800,000.00 | N/A |
| Revenue This Year | $10.32 | N/A |
| Revenue Next Year | $6.71 | $492.11 |
| P/E Ratio | $25.22 | ★ N/A |
| Revenue Growth | ★ 12.11 | N/A |
| 52 Week Low | $137.45 | $56.68 |
| 52 Week High | $206.08 | $200.00 |
| Indicator | AWI | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 53.94 | 46.80 |
| Support Level | $161.33 | $148.06 |
| Resistance Level | $198.38 | $171.59 |
| Average True Range (ATR) | 4.27 | 7.08 |
| MACD | 0.63 | -0.59 |
| Stochastic Oscillator | 52.27 | 20.62 |
Armstrong World Industries Inc designs and manufactures exterior architectural applications, including ceilings, specialty walls, and exterior metal solutions, using materials such as mineral fiber, fiberglass, metal, felt, architectural resin and glass, wood, wood fiber, and glass-reinforced-gypsum. Its segments include Mineral Fiber, which produces suspended mineral fiber and fiberglass ceiling systems and includes results from the Worthington Armstrong Venture (WAVE) for ceiling suspension system (grid) products; Architectural Specialties, which designs, produces, and sources specialty ceilings, walls, and other architectural applications for commercial settings, with revenues mainly project driven; and Unallocated Corporate. The company operates in the United States and Canada.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.